A Systematic Literature Review of the Efficacy and Safety of the Prostar XL Device for the Closure of Large Femoral Arterial Access Sites in Patients Undergoing Percutaneous Endovascular Aortic Procedures  by Haulon, S. et al.
Eur J Vasc Endovasc Surg (2011) 41, 201e213REVIEW
A Systematic Literature Review of the Efficacy and
Safety of the Prostar XL Device for the Closure
of Large Femoral Arterial Access Sites in Patients
Undergoing Percutaneous Endovascular
Aortic ProceduresS. Haulon a,*, R. Hassen Khodja b, C.W. Proudfoot c, E. Samuels caVascular Surgery, Hoˆpital Cardiologique, CHRU Lille, INSERM U1008, Lille, France
bVascular Surgery, Hoˆpital Saint Roch, NICE Cedex 1, France
cHeron Evidence Development, Ltd. Stopsley, UK
Submitted 23 July 2010; accepted 26 October 2010
Available online 8 December 2010KEYWORDS
Percutaneous access;
Abdominal aortic
aneurysm;
Thoracic aortic
aneurysm;
Hospitalisation;
ReviewTo access continuing medical
* Corresponding author. Tel.: þ33 32
E-mail address: Stephan.haulon@c
1078-5884/$36 ª 2010 European Socie
doi:10.1016/j.ejvs.2010.10.015Abstract Objectives: To identify and analyse existing evidence from published studies eval-
uating the efficacy and safety of a percutaneous vessel closure device for the closure of large
arterial femoral arterial access sites (10 French).
Design: This study was a systematic literature review and meta-analysis.
Materials and methods: Electronic databases were searched for studies published on the eval-
uation of the Prostar XL vessel closure device. There was no restriction by study design or
patient population. Appraisal of studies for inclusion and data extraction were performed inde-
pendently by two reviewers. Meta-analysis was performed where feasible.
Results: Twenty-one studies were included, which reported data specifically for closure of
large (10 Fr) femoral arterial access sites using the Prostar XL device. The Prostar XL device,
used for closure of these large femoral artery access sites, had a high rate of procedural
success equal to that reported for closure by femoral artery surgical cut-down. There was
evidence for reduced procedural time, time to discharge and time to ambulation. Complica-
tion rates were lower, but not significantly so, with Prostar XL vs. surgical cut-down.education questions on this paper, please go to www.vasculareducation.com and click on ‘CME’.
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202 S. Haulon et al.Conclusions: TheProstar XL is an effective and safe device for use in percutaneous closure of large
(10 Fr) femoral artery access sites, comparable to open surgical femoral artery cut-down.
Furthermore, it may reduce procedure times and hospitalisations, thereby leading to potential
cost savings.
ª 2010 European Society for Vascular Surgery. Published by Elsevier Ltd. All rights reserved.Table 1 Medline search strategy.
Line Search string
1 (percutaneous adj3 repair).mp.
2 (arteri$ or artery or aorta or aortic).mp.
3 1 and 2
4 aneurysm.mp.
5 4 and 2
6 (arterial puncture closing device$ or arterial
puncture closure device$).mp.
7 (arterial vascular surgery device$ or arterial
vascular surgical device$).mp.
8 (percutaneous closing device$ or percutaneous
closure device$).mp.
9 (percutaneous vascular surgery device$ or
percutaneous vascular surgical device$).mp.
10 femoral closure$.mp.
11 (suture-mediated closure device$ or suture-mediated
closure device$).mp.
12 (large hole closure).mp.
13 (pre-close technique).mp.
14 prostar.mp
15 3 or 5 or/6e14, Limit yr Z “1995eCurrent”Introduction
Haemostasis of small femoral arterial access sites
(<8 French) can be achieved via manual compression at the
vascular access site. Manual compression is associated with
a need for extended bed rest, involving patient discomfort,
resource use and cost implications, and, therefore,
a number of vascular closure products now exist for the
closure of small (5e8 Fr) femoral arterial access sites,
including collagen plugs (Angioseal, St Jude Medical, St
Paul, MN, USA); balloon-positioning catheters (Duett,
Vascular Solutions, Minneapolis, MN, USA); clip-based
closure (StarClose SE, Abbott Vascular, Santa Clara, CA,
USA); sealing agents (Mynx, AccessClosure, Mountain View,
CA, USA); and sutures for placement around the femoral
artery (Prostar XL Percutaneous Vascular Surgical Device,
Perclose ProGlide Suture-Mediated Closure System, Abbott
Vascular, Santa Clara, CA, USA).1
These vascular closure devices have been primarily
developed for peripheral interventions. Endovascular exclu-
sion of abdominal aortic aneurysms (AAAs), thoracic aortic
aneurysms (TAAs) and percutaneous aortic valve replacement
use larger (12e24 Fr) sheaths at the insertion site for their
delivery system (most frequently the common femoral artery
(CFA)). A totally percutaneous access to the CFA for endo-
vascular procedures would potentially avoid the complica-
tions of a groin cut-down to access the femoral artery and
therefore accelerate patient discharge, thus limiting the
overall in-hospital cost.
The primary aim of this article was to determine the
efficacy and safety of the Prostar XL device (Abbott Vascular,
Santa Clara, CA, USA), the only CE Mark-approved percuta-
neous vascular surgical device for closure of large-size
(10 Fr) femoral arterial punctures.2 The Prostar XL is
designed for the repair of femoral artery puncture sites using
sheaths ranging from8.5 Fr to 10Fr. In 2009,CEMark approval
and Canada Health approval was obtained to treat puncture
sites up to and including 24 Fr, and it has been reported in the
literature to treat puncture sites using sheaths ranging from
8.5 to 24 Fr. Where available, data comparing femoral artery
surgical cut-down with the use of the Prostar XL system to
close femoral artery access sites (technical success, proce-
dural time and patient recovery times) were analysed. To
close femoral artery access sites greater than 10 Fr, a ‘pre-
close’ technique is used whereby the sutures of the Prostar
XLdevice areplacedat thearteriotomyat thebeginningof an
intervention without tying the knots down to the arterial
surface. The technique is described in detail in the Interna-
tional IFU for the Prostar XL Percutaneous Vascular Surgical
System.2 At the end of the case, after withdrawal of large
bore sheaths and while the guidewire is in place, the knots
are advanced to the arteriotomy. When haemostasis is
confirmed, the guidewire may be removed.Methods
Data sources
Medline and EMBASE (using the Ovid interface) and the
Cochrane Central Trials Register were searched for studies
published between 1 January 1995 and 1 May 2009 that
involved the use of vascular closure devices in patients of
any age and gender requiring suture-mediated closure of
large femoral arterial access sites, irrespective of the
comparator device or method used. The search strategy
used for Medline is shown in Table 1.
Citations detected by the literature search were initially
screened on the basis of their abstracts. Fulltexts were
obtained for all citations that could potentially meet the
eligibility criteria and were again screened.
Inclusion criteria
Studies reporting use of a device for closure of femoral
arterial punctures of size 10 Fr and above were included. All
patient populations were included, regardless of surgical
procedure. Randomised controlled trials (RCTs), non-rand-
omised controlled trials, observational studies, case-series
and case reports were included. Reviews, editorials and
letters were excluded. Only English-language publications
were included.
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Data from included studies were extracted. Two independent
reviewers extracted each study in parallel; following this,
each pair of extraction grids was compared and any differ-
ences were reconciled by a third, independent reviewer.
Where more than one publication was identified describing
a single study, the data were compiled into a single entry in
the data extraction table. Endpoints extracted were:
proportion of procedural successes as measured by patients;
proportion of procedural successes asmeasuredbyaccess site
closures; total procedural time; time to ambulation; time to
discharge; incidence of complications (as a whole); incidence
of haemorrhage; incidence of haematoma; transfusion
requirement; and costs. Definitions of each outcome were
according to individual study; there is therefore the possi-
bility that these definitions may have differed between
studies, but, in the absence of comprehensive information on
outcome definition, this was considered the best method to
extract the data available. For example, studies may have
differed in definition and reporting of ‘complications’, but as
there is no standard measurement of what constitutes
a complication, extracting data from all studies reporting this
outcomewasdeemed themost validmethod.Wherepossible,
the outcome definition was also extracted to aid interpreta-
tion of the data.
All study designs were incorporated in the review to
include all possible relevant evidence on the Prostar XL.
Unfortunately, a large proportion of the available evidence
comes from small-scale and uncontrolled studies.
Where possible, meta-analysis of comparative data was
performed to analyse the efficacy and safety of the Prostar
XL compared with open surgical cut-down. In addition, we
also pooled data from non-comparative studies (i.e., studies
that only presented data for the Prostar XL), to provide
a pooled estimate of event rates with the Prostar XL. While
the latter analysis is somewhat limited and does not provide
information to compare the Prostar XL with surgical cut-
down, given the relative lack of comparative studies this
analysis was performed to synthesise all relevant studies to
provide the fullest possible picture of the efficacy and safety
of the Prostar XL. Meta-analysis was performed using Stata
statistical software (Intercooled version 9.2 for Windows)
using the metan version 9 add-in.3 Effect sizes for dichoto-
mous outcomes were presented as risk ratios, and effect
sizes for continuous outcomes as the weighted mean differ-
ence between treatments. Fixed-effects estimates were
calculated according to the ManteleHaenszel model, and
random-effects estimates according to the method of Der-
Simonian and Laird. Due to the variation between studies in
terms of design and patient population, it was judged that
the greater degree of between-study heterogeneity assumed
in the random-effects model was more suitable for the data
being analysed; and, hence, random-effects analyses are
presented here. I-squared values were calculated as
a measurement of heterogeneity and typically indicated
a relatively high degree of heterogeneity, supporting the use
of random-effects analysis.
The review was conducted and reported in line with
Preferred Reporting Items for Systematic Reviews and Meta-
Analyses (PRISMA) guidelines, the most current guidelinesextant on systematic review methodology (the initial set-up
of the review followed the earlier quality of reporting meta-
analyses standards (QUOROM) guidelines; following publi-
cation of the PRISMA guidelines in July 2009, the review was
reported in accordance with PRISMA).4
Results
The flow of studies through the review according to PRISMA
guidelines is shown in Fig. 1. A total of 729 studies were
retrieved from searching the literature databases; after
a review of abstracts, 204 full-text citations were obtained
for detailed evaluation. This resulted in 20 studies, which
met the inclusion criteria for this review and provided data
specifically for use of the Prostar XL device to close femoral
arterial access sites of size 10 Fr. There were only seven
studies, which compared the use of the Prostar XL with
femoral arterial surgical cut-down. These studies are sum-
marised in Table 1.
The included studies consisted of one RCT and 19 obser-
vational studies published between 1999 and 2009. These
studies ranged in size fromonepatient in a case report5 to 189
patients in one observational study,6 but, in general, were
relatively small, uncontrolled studies; and these limitations
should be kept in mind when interpreting the evidence. The
majority of studies (15) were based in the USA. By far the
most common procedure evaluated was AAA, investigated by
11 studies, with a further six studies investigating endovas-
cular treatment of aneurysms in general and included
patients with TAAs as well as AAA (Table 1).
Meta-analysis was performed where feasible; a summary
of all meta-analysis results is provided in Table 2.
Efficacy
Rate of procedural success (access site)
Twelve included studies reported the success rate in terms
of the number of access sites closed.516 Success rates for
the Prostar XL varied from 64.4%6e100%.9 Definitions of
success were broadly similar between studies: mainly, the
definition of success was adequate haemostasis withoutFigure 1 PRISMA diagram.
Table 2 Characteristics of included studies.
Study Disease Study
inclusion
criteria
Device Details of
procedure
(technique
and number
of devices used)
Catheter
sheath
size
N Access
site
success
rate,
n (%)
Technical
success
rate by
patient,
n (%)
RCT
Torsello 200322 Abdominal
aortic
aneurysm
(n Z 28)
or thoracic
aortic
aneurysm
(n Z 2)
Patients requiring
endovascular repair
of an aneurysm of
the abdominal area.
Prostar
XL 10
One Prostar XL
10 device used
in the Preclose
technique
14 Fr 15 NR 14/15
(93%)
Surgical
cut-down
15 NR 15/15
(100%)
Observational
studies
Borner 20048 Abdominal
aortic
aneurysm
Abdominal aortic
aneurysm patients
undergoing endovascular
repair with a trimodular
stent-graft who did not
require open repair of
the femoral vessels to
repair a significant lesion
in the common, superficial,
or deep femoral artery.
Prostar
XL 10
One 8 Fr device
and one 10 Fr
device used
in the Preclose
technique
14e20Fr 95 170/
190
(89%)
78/95
(82%)
Surgical
cut-down
26 NR NR
Howell 200211 Abdominal
aortic
aneurysm
Patients undergoing
abdominal aortic
aneurysm repair
with the AneuRx
stent graft.
Prostar XL 10 One 8 Fr device
and one 10 Fr
device used in
the Preclose
technique
22 and 16 Fr
(contralateral)
30 58/60
(97%)
28/30
(93%)
Surgical
cut-down
96 NR NR
Jean-Baptiste
200812
Abdominal
aortic
aneurysm
Abdominal aortic
aneurysm patients
treatable via bifurcated
endograft. Patients with
aortic aneurysm rupture,
circumferential femoral
artery calcification or
hostile femoral triangles
were excluded.
Prostar
XL 10
Two 10 Fr devices
on the side for the
main body graft;
one 10 Fr device
on contralateral
side
18e24 Fr
(main body)
and 12e16 Fr
(contralateral)
19 35/38
(92%)
17/19
(89%)
Surgical
cut-down
21 38/42
(90%)
19/21
 90%)
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Morasch
200423
Abdominal
aortic
aneurysm
Patients who underwent
endovascular repair of an
abdominal aortic aneurysm
with the Gore Bifurcated
Excluder endograft.
Prostar
XL 10
One Prostar XL
10 device used
in the Preclose
technique
12 and 18 Fr 47 NR NR
Surgical cut-
down
35 NR NR
Najjar
200719
Ruptured
abdominal
aortic
aneurysm
Patients with ruptured
abdominal aortic aneurysms
with documented contained
or free rupture (not just
symptomatic).
Prostar
XL 10
One Prostar XL
10 device used
in the Preclose
technique
12e18 Fr 15 NR 15/15
(100%)
Surgical
cut-down
22 NR NR
Peterson
200520
Acute
thoracic
aortic
transection
Patients who had experienced
severe blunt trauma and
underwent endovascular
repair for thoracic aortic
transaction in the acute
setting.
Prostar
XL 10
One Prostar XL
10 device used
in the Preclose
technique
18 Fr 7 NR 7/7
(100%)
Surgical
cut-down
4 NR 4/4
(100%)
Rachel
20026
Abdominal
aortic
aneurysm
Patients who underwent
aortic aneurysm repair.
Patients undergoing open
aneurysm repair or thoracic
aneurysm repair
were excluded.
Prostar XL 8 89 84/89
(91%)
NR
Prostar XL
8/10
combined
One Prostar XL
10 and one Prostar
XL 8 were used to
close 16 Fr access sites.
16 Fr 55 47/55
(85%)
NR
Prostar
XL 10
Two Prostar XL 10
devices were used
to close 22 Fr access
sites.
22 Fr 45 29/45
(64%)
NR
Watelet
200616
Abdominal
aortic
aneurysm
(n Z 20)
or thoracic
aortic
aneurysm
(n Z 9)
Patients undergoing endovascular
repair for abdominal aortic
aneurysms or thoracic aortic
aneurysms without implantation
of an aorto-uni-iliac endograft,
heavily scarred groin, inguinal
arterial prosthesis or severely
calcified femoral arteries with
anterior calcifications.
Prostar
XL 8
and 10
combined
Two Prostar
XL 8 devices
were used to
close 22e24 Fr
access sites and
one Prostar XL 10 was
used to close 16 Fr
access sites. Some
results were
reported
separately for
the Prostar XL 10.
16e22 Fr 29 39/47
(83%)
21/29
(72%)
(continued on next page)
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Table 2 (continued)
Study Disease
Study
inclusion
criteria Device
Details of
procedure
(technique
and number
of devices used)
Catheter
sheath
size N
Access
site
success
rate,
n (%)
Technical
success
rate by
patient,
n (%)
Haas 19999 Abdominal
aortic
aneurysm
Patients undergoing
endovascular
stent and stent-graft
procedures
for abdominal aortic
aneurysm
exclusion.
Prostar
XL 10
One Prostar XL
closure device
was used to suture
arterial access sites
up to 16 Fr in
diameter, two
devices were used
to close 22 Fr access
sites (in one patient).
16e22 Fr 12 13/13
(100%)
12/12
(100%)
Howell 200117 Abdominal
aortic
aneurysm
Patients undergoing
endovascular
abdominal aortic aneurysm
repair. Patients with heavy
femoral arterial calcification
or
receiving aortomonoiliac
endografts
were excluded.
Prostar
XL 10
One 10 Fr Prostar XL
device was used.
16 Fr 144 NR 136/144
(94%)
Quinn
200221
Aortic
dissection
Patients with aortic
dissection (no other
criteria reported).
Prostar
XL 10
Two 10-Fr
Prostar XL
devices
were used
14e20 Fr 15 NR 14/15
(93%)
Arthurs
20087
Aortic aneurysm
(N unclear) or
thoracic
aortic
aneurysm (7
patients)
Patients who underwent
endovascular aneurysm
repair with percutaneous
closure of >12 F access
sites with offelabel of
use of Prostar XL.
Prostar
XL 10
One 10 Fr Prostar
XL device
>12 Fr (some
patients had
20 Fr)
88 145/152
(95%)
84/88
(95%)
Quinn 200424 Abdominal aortic
aneurysm (n Z 42),
iliac aneurysm (n Z 7),
thoracic aortic
transaction
(n Z 1), thoracic
dissection
(n Z 8), thoracic
aneurysm (n Z 4), or
stent-graft
revision (n Z 1)
Patients undergoing
stent-graft procedures
where Perclose devices
are used in femoral
arterial sites.
Prostar
XL 10
One device was
used for 12 Fr
sheaths, and two
devices for >12 Fr
sheaths.
12e16 Fr
sheaths
63 NR NR
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Traul
200015
Abdominal
aortic
aneurysm.
Patients undergoing
abdominal aortic repair
via a stent-graft device,
without heavily calcified,
small iliac arteries.
Prostar
XL 10
Two 10 Fr devices on
the side for the main
body graft; one 10
Fr device
on contralateral side
22 Fr (main
body) and
16 Fr
(contralateral)
17 19/30
(63%)
9/17
(53%)
Heyer
200910
Abdominal
aortic
aneurysm
Abdominal aortic aneurysm
patients treated
percutaneously
using the Zenith
endograft (no
other criteria
reported).
Prostar
XL 10
One 10 Fr Prostar
XL device was used.
20e22 Fr
(main body)
and 16e18 Fr
(contralateral)
14 27/28
(96%)
13/14
(93%)
Marchant
200018
Aortic
stenosis
Patients undergoing
aortic
valvuloplasty
(no other
criteria reported).
Prostar
XL 10
One 10
Fr Prostar
XL device
was used.
14 Fr 4 NR 4/4 (100%)
Starnes
200613
Abdominal
aortic
aneurysm
(n Z 46),
thoracic aortic
aneurysm
(n Z 2),
or infrarenal
aneurysm (n Z 1)
Patients with
peripheral
vascular disease
undergoing
diagnostic or
interventional
vascular procedures
(no
other criteria reported).
Prostar
XL 10
One 10
Fr Prostar
XL device
was used.
1225Fr 49 74/79
(94%)
NR
Teh 200114 Abdominal
aortic
aneurysm (n Z 42),
thoracic aortic
aneurysm (n Z 1),
or iliac aneurysm
(n Z 1)
Patients undergoing
percutaneous repair
of aortic aneurysms
(no other criteria
reported).
Prostar
XL 10
One 10 Fr
Prostar XL
device was
used.
18e20 Fr
(main body)
and 16e18 Fr
(contralateral)
44 70/82
(85%)
33/44
(75%)
Krajcer 20005 Abdominal aortic
aneurysm
N/A (case report for a
single individual).
Prostar
XL 10
The left femoral
artery was percutaneously
sutured with a 10 Fr
and 8 Fr percutaneous
vascular surgery
device; the right
femoral artery was
percutaneously
sutured with 10 Fr
PVS device
22 Fr 1 2/2
(100%)
1/1
(100%)
Note: NR Z not reported.
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208 S. Haulon et al.requirement for surgical cut-down, although one study also
required no complications requiring medical or surgical
intervention within 30 days.12
Only one study compared the Prostar XL with surgical
cut-down: very high rates of success (>90%) were achieved
with both approaches, where success was defined as
percutaneous closure of the arteriotomy without any loco-
regional complications requiring medical therapy or
surgical conversion within 30 days of the procedure.12
The weighted average success rate (95% confidence
interval (CI)) from the studies, which provided data specifi-
cally for the Prostar XL, was calculated as 91% (87e95%).516
Rate of procedural success (patients)
Sixteen of the included studies reported the success rate in
terms of the number of patients in whom successful closure
was achieved.5,712,1422 Two observational studies
compared success rates with the Prostar XL to surgical cut-
down; rates were approximately equal in both arms.12,20 In
the first study, success was defined via completion angiog-
raphy demonstrating apposition of stentgrafts to the aortic
wall, normal perfusion of the aortic branches and exclusion
of the aortic transection without evidence of extravasation;
success rates were 100% in both arms (N Z 7 for surgical
cut-down, N Z 4 for Prostar XL). In the second study,
success was defined as closure with the absence of any
loco-regional complication requiring medical treatment or
surgical intervention within 30 days of surgery (N Z 21 for
surgical cut-down, N Z 19 for Prostar XL).
Across all studies reporting this outcome, successful
arterial closure was achieved in between 53%15 and 100% of
patients using the Prostar XL device.5,9,18,20 The article by
Traul15 described their “initial experience” with the pre-
close technique with a success rate of 53%, and “A detailed
look at reasons for device failure has proven helpful in
revising our techniques and informing others about the
potentials problems with this technique.”15 Meta-analysis
of data from all studies reporting success rates for the
Prostar XL provided a pooled estimate of 89% (84e94%;
random-effects analysis).5,7e12,14e22Table 3 Meta-analysis results summary.
Outcome Effect
measure
Abs
n/N
pat
num
Absolute rate
of procedural
success (access sites)
Average success
rate with Prostar
XL
624
Absolute rate of
procedural success
(patients)
Average success rate
with Prostar XL
426
Total procedural
time
Difference in procedural
time between Prostar XL
and surgical cut-down
(weighted mean)
N Z
Complication rate Risk ratio for complications
(risk with Prostar XL 10 vs.
Risk with surgical cut-down)
N ZTotal procedural time
Ten of the included studies present data relating to the
total procedure time.7,8,1013,15,18,19,22 Six of those studies
compared femoral artery access site closure using the
Prostar XL to femoral arterial surgical cut-down; mean total
procedural times are shown in Table 4.
Meta-analysis of the three studies, which provided data in
a form suitable formeta-analysis (provided patient numbers,
mean and standard deviation or CIs), was performed. The
analysis found that there was a significant reduction in total
procedural time with the Prostar XL compared with surgical
cut-down.11,19,22 This difference was approximately 1 h. The
random-effects meta-analysis identified a weighted mean
difference of 62.4 min (27.8e97.1 min) (Fig. 2).
In addition to the meta-analysed studies, Morasch repor-
ted significant reductions in procedural times with the Pros-
tar XL compared with surgical cut-down and also noted
a significant reduction in total anaesthesia timeand in theuse
of general anaesthesia.23 By contrast, Jean-Baptiste repor-
ted no significant difference in mean surgical time between
theProstar XL and surgical cut-down,12while Borner reported
no significant difference in median procedural time for the
same comparison.8
Time to discharge
Eleven of the included studies reported data relating to the
time to discharge.5,8,1013,18,19,21,23 Overall, the mean time
to discharge with the Prostar XL ranged from 1 day11 to 7
days.21
Four studies compared the Prostar XL to surgical cut-
down for this outcome, although data were not reported in
a way, which allowed meta-analysis.8,12,19,23 In all four,
time to discharge was less in the Prostar XL group, with
reductions ranging from 0.423 to 8.5 days.19 The reduction
was significant in only one of the four studies.19
Time to ambulation
Four of the identified studies presented data relating to the
time to ambulation.5,2224 Mean time to ambulation varied
from 0.1724 to 0.84 days22 for the Prostar XL.olute rate,
OR total
ient
ber
Pooled result,
effect size
(95% CI) e random-
effects model
Pooled result,
effect size (95% CI)
e fixed-effects
model
/692 91% (87%e95%) 92% (91e94%)
/481 89% (84%e94%) 92% (90e95%)
193 62.4 (27.8e97.1) min 66.1 (57.7e74.4)
189 0.87 (0.41e1.88) 0.94 (0.51e1.72)
Table 4 Costs included in Jean-Baptiste 2008.
Prostar XL 10 group Cost in open surgical cut-down
group (V)
p-value
Operating room usage Equal in both groups
Prostar XL device cost V185 V0
Length of stay in hospital 5.8 days 7.8 days
Cost per day in hospital V962 V962
Hospitalisation cost V5579.6 V7503.6 0.04
Total cost (including
hospitalisation cost and use
of 3 Prostar XL devices per
patient)
V6134.6 V7503.6 0.31
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for this outcome. Notably, the RCT by Torsello found a mean
time to ambulation of 20 h in the Prostar XL group compared
with33h in the group receiving surgical closure,22 a significant
reduction of 40% (p < 0.001). By contrast, the observational
study by Morasch reported similar times to ambulation (0.8
days) in both patients receiving surgical cut-down and
patients in whom the Prostar XL device was used.23 Meta-
analysis of these two studies was not possible.
It should be noted that the time to discharge/ambulation
is determined by the unblinded surgeon, and is therefore
susceptible to bias.
Safety
Complication rate
Sixteen included studies reported data relating to compli-
cation rates.5,7,9,1122,24 The defined complications varied
between individual studies, limiting synthesis of the data to
those studies with comparable definitions.Figure 2 Procedural time ranFive studies compared complication rates with the
Prostar XL to complication rates for surgical cut-down. Four
of these were suitable for meta-analysis (in the fifth study,
complication rates were zero in both arms).20 The risk ratio
for the Prostar XL compared with surgical cut-down is 0.87
(0.41e1.88), suggesting a lower risk with the Prostar XL
(not statistically significant). Similarly, individual studies
indicated a reduction in complication rates with the Prostar
XL but these were not significant and further studies are
needed to explore this.6,22,23
A range of different complications is taken into account
when complications rates are reported, and it is important
to note that the different complications differ in severity.
For example, the Prostar XL may be associated with
increased bleeding events, particularly in obese
patients,7,13,14,22 with lower rates of complications such as
lymph leak and lymphoceles, which can be experienced
with cut-down.12,22 Severe long-term complications may
also occur less frequently with the Prostar XL than with
cut-down.7dom-effects meta-analysis.
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Nine of the included studies reported data relating to the
rate of haemorrhage.9,11,12,14,15,18,2224 Quoted rates of
haemorrhage observed with the Prostar XL varied from
0%11,18 to 14.9%.23
Only one study compared the Prostar XL to surgical cut-
down; this was the RCT by Torsello, which reported that
one patient in the Prostar XL group required arterial
suturing of the access artery due to bleeding, whereas none
of the patients in the surgical cut-down arm experienced
haemorrhage.22 In this case, the guidewire was previously
removed, which is not standard procedure described in the
preclose technique, and temporary haemostasis could not
be achieved with a catheter balloon. None of the compar-
ative observational studies reported haemorrhage rates for
both the Prostar XL and surgical cut-down.
Rate of haematoma
Nine of the identified studies present data relating to the
rate of haematoma.5,7,911,13,17,18,23 Rates of haematoma
varied from 0% reported in a number of studies5,911,13,17,18
to 4.5% in the study by Arthurs.7
Only one study compared the Prostar XL with surgical
cut-down23; there was no clear difference in haematoma
rate between the two arms (4.3% with Prostar XL; 5.7% with
surgical cut-down).
Rate of transfusion
Six of the identified studies present data relating to the
rate of transfusion.7,11,15,19,22,23
Torsello reported that no patient received transfusion in
either the Prostar XL or the surgical cut-down group.22
Two observational studies compared the Prostar XL to
surgical cut-down.19,23 In one study, the rates of trans-
fusions were reported both for the index hospitalisation and
as secondary to access-site complication, and were similar
in both groups.23 In the second study, the Prostar XL used in
percutaneous endovascular surgery was compared with
open vascular surgical repair of ruptured AAAs, and,
therefore, the two groups are not comparable in terms of
transfusion requirements.19
The other studies were non-comparative. In general,
there was considerable variation in the rate of transfusion,
from 0%11 to over 50% in the study by Traul.15 The high value
recorded may be because this study recorded transfusions
during the entire hospitalisation period as opposed to only
during the surgical procedure. The authors compared this
to their prior experience with open surgical cut-down of the
femoral artery access site, where the transfusion rate was
generally lower (28%).
Costs
The study by Jean-Baptiste was conducted in France, and
reported costs for the Prostar XL compared with surgical
cut-down.12 The total cost including hospitalisation cost
and the use of the device was lower in the Prostar XL group
(V6134.60 per patient) compared with the surgical cut-
down group (V7503.60 per patient; Table 3). This was not
significant (p Z 0.31). Hospitalisation costs, not including
the cost of the device, were however significantly lower in
the Prostar XL group (V5579.60 vs. V7503.60, p Z 0.04).
Although there was no significant difference in total costs,the data suggest it is possible that the savings in hospital-
isation cost associated with the Prostar XL may be able to
compensate for the additional cost of the device.12
The RCT reported by Torsello, conducted in Germany,
also reported costs as an outcome. The cost of materials in
the Prostar XL group was significantly higher compared with
the surgery arm, but the cost for operating time use was
significantly reduced (V251 vs. V357.6). The overall cost
was V99 higher in the percutaneous Prostar XL group,
mainly due to the cost of the device.22Discussion
Only one device, the Prostar XL Percutaneous Vascular
Surgical Device, was identified in use for closure of large
(10 Fr) femoral arterial access sites. This is as expected,
as this is currently the only device indicated for such use.
The Prostar XL device was associated with a rate of
procedural success equivalent to that observed with
surgical cut-down, as measured by access site or patients.
Therefore, this device is shown to be as effective as
surgical cut-down. (Table 5)
Meta-analysis and results of individual studies suggest that
the Prostar XL was associated with a statistically significant
reduction in total procedural time of approximately 1 h.
Given the serious nature of the procedures in which the
Prostar XL is used (most commonly, endovascular repair of
AAA in the studies in our review), if such a reduction is
possible, it is likely to be clinically meaningful and may
potentially even have implications for improved patient
safety. This finding is in line with two recent meta-analyses,
which demonstrate a significant reduction in time to hae-
mostasis/total operative time with vascular closure
devices.25,26 Reductions in total surgical procedural time
could also have implications for operating theatre
throughput. There are a number of factors, which affect
throughput in theatres and, therefore, if theProstar XL is able
to reduce procedural times, it will have to be combined with
other management strategies to increase the number of
procedures per theatreday.
Included studies suggested that the use of the Prostar XL
device might reduce time to discharge and time to ambu-
lation, although, in most cases, these reductions were not
statistically significant, and these two outcomes are
susceptible to bias. Therefore, the extent to which the
Prostar XL could contribute to timesavings with these
outcomes is still unclear. If this is borne out by further
studies, such timesavings could be economically important
in terms of reduced resource requirement by patients.
These timesavings have the potential to significantly
benefit patients, by reducing the time they spend immobile
and in the hospital, and reduce resource use as well as
potentially improving quality of life. Reductions in patient
length of stay, particularly in surgical recovery wards, can
lead to considerable cost savings for hospitals. Time to
ambulation determines the time period over which patients
require intensive monitoring and care by medical staff,
and, therefore, reductions in time to ambulation may lead
to reductions in staff resource use and costs.
Two studies included in this article indicated a potential
for costsavings with use of the Prostar XL. One study showed
Table 5 Studies reporting total procedural time, Prostar XL vs. surgical cut-down.
Study Device N Mean (SD) time,
minutes
Statistical
significance
Comments
RCT
Torsello 200322 Prostar XL 10 15 86.7 (27) p < 0.05 Total operative time
Surgical cut-down 15 107.8 (38.5)
Observational studies
Borner 20048 Prostar XL 10 95 180 (100e425) e Total operative time
Median (range)
Surgical cut-down 26 175 (100e305)
Median (range)
Howell 200211 Prostar XL 10 30 105 (21) p < 0.0001 Measured from the initial
arterial access puncture to
surgical closure of the femoral
artery access site.
Surgical cut-down 96 171 (33)
Jean-Baptiste 200812 Prostar XL 10 19 130 p Z 0.54 Total operative time
Surgical cut-down 21 122
Morasch 200423 Prostar XL 10 47 139 p Z 0.002 Total operative time. Total in-
room anaesthesia time was also
reduced (201 min vs. 225 min;
p < 0.008), and use of general
anaesthesia was reduced
(p < 0.001).
Surgical cut-down 35 169
Najjar 200719 Prostar XL 10 15 107 (30)
(range: 67e160)
p < 0.05 e
Surgical cut-down 22 205 (31)
(range: 175e240)
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costs were higher with the Prostar XL.22 It was clear from
these studies that some costs (operating room and hospi-
talisation costs) may be reduced with device use, in agree-
ment with the results on time-related outcomes, while
others are increased (such as cost of materials for proce-
dures). More research into this would be beneficial to
determine whether the Prostar XL is indeed associated with
a reduction in total medical costs of the endovascular
procedures in which it is used.12,22 It should be emphasised
that no evidence is currently available on the cost-effec-
tiveness of the Prostar XL device compared with surgical cut-
down; hence, the end costs may vary with differences in the
technique and experience of the surgeons using the device.
This is especially the case during the learning curve period,
as success is dependent upon operator experience.27
No significant difference between the Prostar XL and
surgical cut-down was shown with regard to complication
rates. Meta-analysis, along with some individual studies,
indicated a lower risk but this was not significant, sug-
gesting further data are needed to confirm this finding.
Limited data were available to compare haemorrhage
rates. Transfusion rates were similar or slightly lower with
the Prostar XL. Only one study provided comparative data
for haematoma incidence; the rates were similar for the
Prostar XL and surgical cut-down.23 Thus, overall, the
Prostar XL is at least as safe as surgical cut-down in terms of
haemorrhage and haematoma.
These results are consistent with findings of a recent
review of vascular closure devices, which identified that
there was no reduction in complication rates with thesedevices.25 Similarly, a systematic review of percutaneous
endovascular aneurysm repair performed mostly with the
Prostar XL found that the device was associated with a low
access-related complication rate compared with open-
access endovascular aneurysm repair.26 The safety findings
of this review are also in agreement with results published
in 2009 from a large-scale prospective observational study
investigating the safety of femoral artery closure using the
Prostar XL in conjunction with the preclose technique,
where the investigators report that Prostar XL is safe and
associated with minimal early and late complications.27
It should also be noted that percutaneous closure devices
such as the Prostar XL might have other advantages over
surgical cut-down. First, the smaller scar reaction at the
level of the groin increases the potential for repeat puncture
of the femoral artery, allowing further vascular access when
necessary. Second, the complications associated with use of
the Prostar XL device, whilst similar in frequency to the rate
of complications associated with surgical cut-down, can
differ markedly in their seriousness and ease of resolution.
There are of course limitations to this review. Much of the
data are derived from small-scale uncontrolled observational
studies. There were differences between studies in the
patient population, type of endovascular procedures per-
formedand the reporting anddefinition of relevant outcomes;
hence, whilst there is a large literature base supporting the
pooling of data from observational studies, it is important to
interpret the results of such pooling with caution.
Further, in this article, we relied on the data reported in
the literature, rather than using patient-level data. These
limitations necessarily limit the confidence of the
212 S. Haulon et al.conclusions drawn. Further, higher-powered controlled
studies would be beneficial in confirming the data reported
here, although there are considerable, well-recognised
difficulties in performing large-scale controlled studies in
the field of vascular surgery. In addition, further studies
based on increased experience in individual institutions
with the Prostar XL may be beneficial. With all new
procedures, there is a ‘learning curve’ effect during which
potential benefits such as time savings may not be
apparent. Therefore, further studies of long-term use are
necessary to quantify benefits, which may be apparent
after the plateau of the learning curve.12,16
Conclusion
Evidence from published studies support the idea that
closure of femoral arterial access sites of size 10e24 Fr with
a device (the Prostar XL with the preclose technique) is as
safe and effective as surgical cut-down. There are consid-
erable limitations in the evidence base, with most studies
being small-scale uncontrolled studies, and therefore there
is considerable uncertainty in the results. However,
although further research is clearly needed to compare the
Prostar XL with surgical cut-down, the current evidence
base suggests that there is the possibility that use of the
device could result in clinically meaningful savings in
procedural time, patient recovery time and patient length
of stay, which may lead to improved safety outcomes and
reduced resource use.
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